2026/05/13 by Yuanyuan Xie, Shangqing Hong, Chenling Xu · 1 voice
Immunology and Microbiology · Medicine · #CAR-T cell therapy research #Immunotherapy and Immune Responses #Reproductive System and Pregnancy
paper · doi:10.64898/2026.05.10.723228
openalex publication_date 2026/05/13 · openalex created_date 2026/05/14 · openalex updated_date 2026/07/14
Abstract Personalized T cell therapy empowered by chimeric antigen receptor (CAR) that recognizes specific tumor antigen has cured numerous blood cancer patients since its initial approval in 2017. However, its access to a broader population has been limited by the unavailability of an off-the-shelf product derived from an allogeneic donor that can evade immune rejection, which is mediated by polymorphic class I and class II human leukocyte antigens (HLAs). Since class II HLAs are only expressed in specialized antigen-presenting cells but not T cells, it might suffice to evade T cells by deleting the common class I HLA light chain Beta-2 Microglobulin (B2M) ( 1 ). However, B2M -deficient cells can trigger a “missing-self” response to activate natural killer (NK) cells ( 2 ), a second function that was evolved to compensate loss of T cell response. Inserting a less polymorphic class I HLA gene encoding a known NK inhibitory ligand, namely HLA-E or HLA-G ( 3 ), into the B2M locus so that the endogenous B2M expression is disrupted could theoretically allow evasion of both T and NK cells. Despite being a seemingly better candidate in that HLA-G is uniquely expressed in immune-privileged sites such as the placenta with a believed function in protecting the fetus from immune rejection by the pregnant mother, whereas ubiquitously-expressing HLA-E is known to bind both inhibitory and activating NK receptors ( 4 , 5 ), only HLA-E engineering has been attempted yet without convincing success in vivo ( 6 , 7 ). Here, we generate an off-the-shelf CAR-T product with B2M replaced by a gene fusion encoding an HLA-G single-chain trimer under minimally impacted B2M epigenetic landscape, and observe its immune evasion property and a tumor-inhibitory function that is equivalent to its autologous control using a humanized mouse model for the first time with T and NK cells reconstituted from a donor with a distant HLA haplotype. HLA-G engineering may thus reprogram T cells into an immune-privileged state that can be utilized for all cell-based therapies.